No Data
Delayed hospital purchases, sluggish non-rigid medical demand, and other factors dragged down shenzhen mindray bio-medical electronics' Q3 net income by 9.31% | Financial report watch
Due to factors such as delayed hospital procurement, tight hospital construction funds, and sluggish non-rigid medical demand, in the third quarter, Shenzhen Mindray Bio-Medical Electronics' net income decreased by 9.31% year-on-year, while total revenue increased by 1.43% year-on-year. In the second interim profit distribution in 2024, Shenzhen Mindray Bio-Medical Electronics will distribute 16.50 yuan for every 10 shares.
R&D expenses continue to rise, autobio diagnostics once again embroiled in a whirlpool of disputes | interpretations
①In the first three quarters of this year, the revenue and net income attributable to shareholders of Autobio Diagnostics have both increased to a certain extent; ②The company has further increased its investment in research and development, with multiple products obtaining medical instruments registration certificates.
Q3 revenue growth rate dropped to 1%. Can the next approved botox product in China be featured on imeik technology development? | Interpretations
①In the first three quarters, imeik technology development's performance has shown some growth, but the revenue and net income attributable to shareholders have slowed down. ②In order to seek new growth points, imeik technology development's research and development expenses continue to rise, focusing on the layout of weight management drugs, botulinum toxin and other fields.
imeik technology development Q3 revenue increased by 1.10% year-on-year, net income increased by 2.13% | Financial Report Watch
In the first three quarters, the company achieved revenue of approximately 2.376 billion yuan, a year-on-year increase of 9.46%; net income was approximately 1.586 billion yuan, a year-on-year increase of 11.79%. The operational scale of the company is steadily increasing, and the profitability meets market expectations.
Chinese concept stocks are once again popular! Morgan Stanley has raised the ratings of multiple Chinese concept internet companies, and these industries are highly favored.
①Australia's well-known bank Macquarie released a report, upgrading the ratings of multiple Chinese internet-related stocks; ②The reason for the upgrade is the improved visibility of profits, as well as the continuous policy support from the Chinese government.
How to Capitalize on the Ongoing Bull Market for Chinese Stocks